Can BlissBio’s HER2-Targeting ADC Challenge Enhertu In Breast Cancer?
Eisai Deal Sets Stage For Battle
A new deal worth up to $2bn-plus with Eisai has put Bliss Biopharmaceutical's HER2-targeting antibody-drug conjugate BB-1701 in the spotlight, as the global race heats up to find a possible challenger to Enhertu.
